Figure 2.

Possible combination therapy strategies to treat chronic HBV. As new therapies to manage HBV become available, it seems likely that combination therapy will be used. Each oval represents a distinct drug in development that is considered either direct acting (blue) or indirect acting (green), based on its mechanism of action. The IDAAs include those that target the host immune systems. One approach will be to first use DAAs to achieve suppression of viremia and antigenemia followed by IDAAs to clear remaining virus and effect functional cure. Abbreviation: RNAi, RNA interference.